Related Experiment Video
Updated: Aug 11, 2026
Isolation and Activation of Murine Lymphocytes
Published on: October 30, 2016
Modulation by ST 789 of in vitro lymphocyte activation and cytokine production
G Famularo1, R Giacomelli, S Sacchetti
1Dipartimento di Medicina Interna e Sanità Pubblica, Universitá dell'Aquila, Italy.
Insights
ST 789 demonstrates complex immunomodulatory effects, inhibiting some immune cell activation while significantly boosting interleukin-6 production. These findings suggest potential clinical applications for ST 789 in treating human diseases.
Area of Science:
- Immunology
- Pharmacology
Background:
- The compound ST 789 exhibits immunomodulatory properties.
- Understanding its precise mechanisms is crucial for potential therapeutic applications.
Purpose of the Study:
- To investigate the immunomodulatory effects of ST 789 on human peripheral blood mononuclear cells (PBMCs) and T cell lines.
- To elucidate the mechanisms underlying ST 789's impact on immune cell activation and cytokine production.
Main Methods:
- Stimulation of PBMCs from healthy subjects with mitogens.
- Assessment of activation antigen expression (interleukin-2, transferrin receptors).
- Measurement of soluble CD8 antigen, interleukin-4, and interleukin-6 production.
- Evaluation of proliferative responses in antigen-specific and autoreactive human T cell lines.
Main Results:
- ST 789 inhibited interleukin-2 and transferrin receptor expression on mitogen-stimulated PBMCs.
- No significant effect was observed on soluble CD8 antigen, interleukin-4 production, or T cell proliferation.
- ST 789 strongly enhanced interleukin-6 production by PHA-stimulated PBMCs.
- Inhibition of activation antigens was not mediated by CD8+ suppressor T lymphocytes, suggesting direct action on T helper cells.
Conclusions:
- ST 789 possesses complex immunomodulatory activities, including inhibition of T helper cell activation and significant enhancement of interleukin-6 production.
- The potent induction of interleukin-6 suggests promising clinical applications for ST 789 in managing human diseases.
Abstract:
Our results indicate that ST 789 exhibits complex immunomodulant properties. In fact, we found that ST 789 inhibits the expression of activation antigens, such as interleukin-2 and transferrin receptors by peripheral blood mononuclear cells (PBMCs) from healthy subjects following mitogen stimulation, but we were not able to detect under the same experimental conditions any effect on the in vitro production of soluble CD8 antigen and of interleukin-4 as well as on the proliferative response of antigen-specific and autoreactive human T cell lines. Finally, we showed that ST 789 is able to strongly enhance the in vitro production of interleukin-6 by PHA-stimulated PBMCs. The reduced expression of activation antigens in the presence of ST 789 does not seem to be mediated by CD8+ suppressor T lymphocytes, as indicated by the normal soluble CD8 levels in culture media, but rather reflects a direct inhibitory action on T helper proliferation and likely on interleukin-2 secretion. The strong enhancement by ST 789 of the in vitro interleukin-6 production seems to indicate the most relevant possibility of clinical applications in human diseases.
